Alcon is the world's largest eye care device company, operating across surgical and vision care. Founded in 1945, the company has spent over 75 years developing treatments and technologies for ophthalmology, operating in 60 countries and serving patients in more than 140. Its portfolio spans surgical equipment, intraocular lenses, contact lenses, pharmaceutical treatments, and diagnostic technologies.
The company invests heavily in research and development, spending over $876 million annually with more than 70 products under development. Flagship offerings include AcrySof intraocular lenses, which represent a foundational technology in cataract surgery, and DAILIES TOTAL1 contact lenses, which employ advanced water gradient technology.
Alcon's scale and breadth position it at the intersection of medical devices, pharmaceuticals, and consumer vision care. The organisation is structured around a mission-centred approach to eye care innovation, reflecting a belief that vision quality directly affects quality of life.
